Asterias Biotherapeutics, Inc. (AST)
(Delayed Data from AMEX)
$NA USD
0 (0.00%)
Updated Mar 7, 2019 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[AST]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Industry: Medical - Biomedical and Genetics
Terminating coverage following BioTime merger announcement.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for AST
Provider: ValuEngine, Inc
Industry: Medical - Biomedical and Genetics
Facilities and Intellectual Property License Agreements Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Type B Meeting Request Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
SCiStar Trial Two-Year Cohort 2 Update Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Positive AST-VAC2 Review From Second Safety Review Committee Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
2Q18 Financial Results Reported; Further SCiStar Cohort Data Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Full Six-Month SCiStar Clinical Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
AST-VAC2 Passes Safety Evaluation; Preclinical Stroke Collaboration Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
AST-VAC2 Lung Cancer Trial Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Final Independent Data Monitoring Committee Review Completed in SCiStar Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
1Q 2018 Financial Results Reported; Spending Declines Substantially; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
AST-VAC2 Trial Approaches Dosing Initiation; OPC1 Data Presentations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
4Q and FY2017 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Further SCiStar Data Reported; Looking Ahead to Development Pathway Clarification; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
3Q17 Financial Results Reported; Lowering Price Target to $11 Upon Recent Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
AST-VAC2 Lung Cancer Trial Clearance Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
2Q17 Financial Results Reported; Looking Ahead to Further SCiStar Efficacy Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.